Trials / Completed
CompletedNCT05471674
Neoadjuvant Anti-PD1 in HCC
Neoadjuvant Immunotherapy With Anti-PD1 in Borderline Resectable Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Dr Tan-to CHEUNG · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2, single-arm trial designed to assess the clinical benefit of treatment with nivolumab administered in patients with untreated, borderline resectable HCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | 3 mg/kg on Day 1 of each 2-weekly cycle for 3 doses |
| PROCEDURE | Hepatectomy | Hepatectomy will be performed approximately 2 weeks after the 3rd dose of nivolumab |
Timeline
- Start date
- 2020-07-03
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2022-07-25
- Last updated
- 2023-02-01
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT05471674. Inclusion in this directory is not an endorsement.